Daniel C. Adelman
2016 - Aimmune Therapeutics
In 2016, Daniel C. Adelman earned a total compensation of $2.2M as Chief Medical Officer at Aimmune Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $76,400 |
|---|---|
| Option Awards | $1,881,050 |
| Salary | $216,667 |
| Total | $2,174,117 |
Adelman received $1.9M in option awards, accounting for 87% of the total pay in 2016.
Adelman also received $76.4K in non-equity incentive plan and $216.7K in salary.
Rankings
In 2016, Daniel C. Adelman's compensation ranked 4,514th out of 14,075 executives tracked by ExecPay. In other words, Adelman earned more than 67.9% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,514 out of 14,075 | 68th |
Division Manufacturing | 1,600 out of 5,486 | 71st |
Major group Chemicals And Allied Products | 494 out of 1,900 | 74th |
Industry group Drugs | 365 out of 1,543 | 76th |
Industry Pharmaceutical Preparations | 288 out of 1,173 | 75th |
Source: SEC filing on April 11, 2018.
Adelman's colleagues
We found three more compensation records of executives who worked with Daniel C. Adelman at Aimmune Therapeutics in 2016.